Inhaltsseite: Home

Yield Enhancement

Growth & Yield: Chinese Tech and Bio-Pharma

Friday, 25 March 2022 Reading time : 1 minute

BRC on Moderna, Biontech and Novavax (USD / CHF)

  • 31% coupon p.a. (USD)
  • 28.7% coupon p.a. (CHF)
  • 50% barrier
  • 12 months
  • Subscription untilApril 11, 2022
  • Valor 113 290 755 (USD)
  • Valor 113 290 756 (CHF)


BRC on Alibaba, Baidu and Nio (USD / CHF)

  • 24% coupon p.a. (USD)
  • 21.3% coupon p.a. (CHF)
  • 50% barrier
  • 12 months
  • Subscription until April 11, 2022
  • Valor 113 290 722 (USD)
  • Valor 113 290 723 (CHF)

Disclaimer
This communication is for marketing purposes. It is neither an offer nor an invitation to submit an offer, to purchase or to subscribe to securities and does not constitute investment advice. You should consult your advisors before making an investment decision.
Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, financial condition, development or performance of the issuer to be materially different from any future results, financial condition, development or performance expressed or implied by such statements.
The present document has not been drawn up by the research department as defined in the rules of the “Directives on the Independence of Financial Research” published by the Swiss Bankers Association, hence these rules do not apply to this document.
If securities are mentioned in the communication, the base prospectus, the final terms and any key information document may be obtained free of charge from Zürcher Kantonalbank, Bahnhofstrasse 9, 8001 Zurich, VRIS, and from www.zkb.ch/finanzinformationen. 

 


Ajax loading